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The value of the initial post-EVAR computed
tomography angiography scan in predicting future
secondary procedures using the Powerlink stent
graft
Mitul S. Patel, MD, and Jeffrey P. Carpenter, MD, Camden, NJ
Objective: Current long-term surveillance after endovascular abdominal aortic aneurysm repair (EVAR) is based on
high-resolution contrast-enhanced computed tomography (CT) scans at scheduled, lifelong intervals. The cancer and
nephrotoxicity risks of interval CT scanning and prolonged radiation exposure are concerning. We sought to determine
if surveillance CT angiography (CTA) can be safely reduced.
Methods: From July 2000 to November 2007, 345 patients were enrolled in U.S. Food and Drug Administration trials of
the Powerlink System (Endologix, Irvine, Calif). An independent core laboratory analyzed 1519 post-EVAR CT scans
(N  1519) to 5 years to evaluate aneurysm size, migration, presence of endoleak, and evidence of graft obstruction.
Analyses were conducted to determine the value of the initial CTA scan in predicting future secondary procedures in
enrolled patients.
Results: At any time during follow-up, CTA identified endoleak in 123 patients (36%), with 95% of endoleaks being type
II. In addition, 49 patients underwent 72 secondary procedures at a mean of 22 21 months (range, 2-2007 days) after
initial EVAR. These were based on clinical identification of limb ischemia in 13 interventions (18%) or core laboratory
identification of abnormal CT finding in 58 interventions (81%). Of the 58 core laboratory identified findings, the
inciting abnormality was present on the initial postoperative scan in 49 (84%). Of the remaining nine CT-driven
procedures, three (5.2%) were due to late sac expansion attributed to type II endoleak (n 2) or endotension (n 1); two
(3.4%) were for prophylactic reasons in the absence of endoleak; and four (6.8%) were in patients with type II endoleak
not observed by the core laboratory and without sac expansion. The negative predictive value of the initial postoperative
CTA for the need for a secondary procedure is therefore 96.4%, which can be improved to 97.6% with duplex ultrasound
surveillance to detect sac expansion. Thus, a negative initial postoperative CTA is highly predictive of long-term freedom
from secondary intervention.
Conclusions: Among enrolled patients with suitable anatomy for EVAR, most abnormalities that result in a secondary
procedure are detected on the initial postoperative CTA or present with clinical symptoms. Long-term surveillance CTA
may therefore be replaced by duplex ultrasound imaging if the initial postoperative CTA shows no abnormalities. ( J Vasc
Surg 2010;52:1135-9.)Since the introduction of endovascular abdominal aor-
tic aneurysm repair (EVAR) reported by Parodi in 1991,
overall morbidity and mortality associated with abdominal
aortic aneurysm (AAA) repair has markedly declined. As
demonstrated in multiple clinical trials and in population-
based observational analyses, patients undergoing EVAR
experience a lower incidence of perioperative mortality and
morbidity, decreased hospital length of stay, and a faster
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surgery.1
Despite its recognized benefits, EVAR is associated
with inherent complications, including device migration
and endoleak formation, potentially leading to aneurysm
expansion and need for secondary intervention to prevent
rupture. Because EVAR mandates lifelong surveillance for
endoleak and aneurysm-related complications, trials of
EVAR devices have relied on high-resolution contrast-
enhanced computed tomography angiography (CTA)
scans for post-EVAR surveillance. On the basis of clinical
and investigational history, the generally accepted post-
EVAR surveillance protocol consists of a CTA scan in the
early postoperative period, followed by serial CTAs at 6
months and annually thereafter.2
Although CTA is currently accepted as the gold stan-
dard for post-EVAR surveillance of endoleak and aneurysm
morphology, concerns regarding the risks of cancer and
nephropathy associated with repetitive radiation and con-
trast exposure, as well as the resources required, have
become major sources of concern.3,4 Accordingly, a num-
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for post-EVAR surveillance. Duplex ultrasound (DU) im-
aging is gaining considerable favor as an alternative due to
its radiologic safety and low cost. However, its utility as an
alternative to long-termCTA surveillance is currently being
evaluated and has yet to be widely established in practice.5-8
We reviewed serial CTA findings during a 5-year
follow-up period after EVAR in relation to endoleak, device
obstruction, and secondary procedures. The objective of
this study was to determine the value of the initial postop-
erative CTA for predicting longer-term need for a second-
ary procedure and thus provide a risk-benefit assessment of
continued long-term CTA surveillance. Furthermore, we
sought to determine whether a normal result on an initial
CTA could possibly be used to route patients to a radiolog-
ically safer and more cost-effective DU surveillance regi-
men.
METHODS
In two prospective, multicenter, controlled trials of the
Powerlink stent graft (Endologix, Irvine, Calif), 345 pa-
tients with nonruptured infrarenal aortoiliac aneurysms
(low surgical risk, good anatomy) enrolled using common
inclusion/exclusion criteria underwent EVAR at 24 centers
from July 2000 to November 2007, with protocol-defined
continuing follow-up to 5 years after implant. Study sites
included both academic and community hospital institu-
tions with research infrastructures, and all were experienced
in AAA treatment.
As described previously elsewhere,9 eligible patients
underwent CTA scanning with 3-dimensional reconstruc-
tion. Scans were analyzed by the sites to determine ana-
tomic suitability for enrollment according to protocol cri-
teria and, ultimately, by the core laboratory (M2S Inc,West
Lebanon, NH) to determine baseline values for analysis. Of
these patients, 192 received the device in the infrarenal
configuration and 153 received the device in the suprarenal
configuration. According to the trial protocols, patients
were monitored for aneurysm morphology and endoleak by
core laboratory evaluation of the high-resolution, contrast-
enhanced CTA at 1month, 6months, 1 year, and annually to
5 years. Four-view kidney-ureter-bladder radiographic eval-
uation was also conducted at the same time. The 5-year
follow-up has been completed for patients who received the
infrarenal device and is ongoing for patients with the supra-
renal device. For the purposes of this analysis, a mean
achieved follow-up time is 4.3  1.8 years for infrarenal
patients and 2.3  1.4 years for suprarenal patients.
Definitions. Endoleak was defined as the presence of
contrast material within the aneurysm sac but outside of the
graft material. Migration was defined as 10-mm move-
ment of the proximal end of the graft from the baseline scan
relative to the lowest most renal artery, or any movement
requiring treatment. Obstruction was defined as possible
stenosis or blockage at any location along the length of the
stent graft or limb.RESULTS
Patients underwent the initial EVAR procedure at a
mean age of 73.0  7.0 years for infrarenal devices and
74.0  8.1 years for suprarenal devices and were predom-
inantly male (89% and 90%, respectively). In compliance
with patient consent and Institutional Review Board over-
sight requirements, clinical follow-up and core laboratory
assessment follow-up of eligible patients have been excel-
lent. All patients with an evaluable CTA scan are included in
this analysis (Table I); only five patients for whom the
requisite CTA imaging was not obtained are excluded from
the analysis. This resulted in 1519 post-EVAR CTAs that
were analyzed by the core laboratory to assess aneurysm
changes, endoleaks, device position, and integrity. En-
doleaks identified by the core laboratory are presented in
Table II. Type II (collateral vessel-related) endoleaks were
observed in 198 of 219 patients (95%), and no type III or
type IV endoleaks were observed. Kaplan-Meier estimates
for freedom from type IA or type IB endoleak are shown in
the Fig. At 5 years, freedom from any type I endoleak was
Table I. Distribution of core laboratory evaluated
computed tomography angiography (CTA) scans after












Table II. Core laboratory-reported endoleaka
Endoleak type Type IA Type IB Type II
1 month
Infrarenal 2.0% (3/152) 0.0% (0/152) 19.1% (29/152)
Suprarenal 4.6% (6/130) 0.8% (1/138) 37.4% (48/138)
1 year
Infrarenal 0.7% (1/138) 0.0% (0/138) 12.3% (17/138)
Suprarenal 2.8% (3/105) 2.8% (3/114) 27.0% (28/114)
2 years
Infrarenal 0.8% (1/119) 0.0% (0/119) 9.2% (11/119)
Suprarenal 2.8% (2/70) 0.0% (0/64) 25.0% (16/64)
3 years
Infrarenal 0.0% (0/103) 0.0% (0/103) 5.8% (6/103)
Suprarenal 1.8% (1/56) 0.0% (0/47) 29.7% (14/47)
4 years
Infrarenal 0.0% (0/97) 0.0% (0/97) 10.3% (10/97)
Suprarenal 0.0% (0/34) 0.0% (0/25) 24.0% (6/25)
5 years
Infrarenal 0.0% (0/87) 0.0% (0/87) 11.5% (10/87)
Suprarenal 0.0% (0/22) 0.0% (0/14) 21.4% (3/14)
aEndoleaks reported are not cumulative but are those identified at each time
point. Some patients had more than one type of endoleak.97% for infrarenal devices and 91% for suprarenal devices.
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49 patients (14% of the cohort) at a mean of 22  21
months (range, 2-2007 days) postoperatively (Table III).
Indications for intervention were type IA or IB endoleak in
18 patients (25% of interventions), type II endoleak in 37
(51%), endotension in 1 (1.4%), device migration in 3
(4.2%), and limb ischemia in 13 (18%). Among these cases,
58 procedures were performed for CT-observed findings.
Notably, the abnormality in 49 (84%) led to intervention
on the initial postoperative CTA. The nine secondary pro-
cedures performed that were not observed on the initial
CTA were for late sac expansion in 3 (5.2%) attributed to
type II endoleak (n  2) or endotension (n  1), for
persistent type II endoleak not reported by the core labo-
ratory and without sac expansion in 4 (6.8%), or were
performed prophylactically in 2 patients (3.4%) with neck
angulation or migration without endoleak. Thus, all but
one abnormality (graft migration without endoleak) was
Fig. Freedom from type IA or type IB endoleak for infra
The blue circles indicate censored infrarenal patients, and
Table III. Indications for secondary procedures
Intervention
Interventions,
No. Days to intervention
(% of total) (range in days)
Type IA or type IB
endoleak 18 (25) 2-2007 (  705)
Type II endoleak 37 (51) 19-1681 (  748)
Endotension 1 (1.4) Day 399
Migration 3 (4.2) 1611-1855 (  1695)
Limb or artery
thrombosis/stenosis 13 (18) 2-1177 (  246)
Total 72 (100) 2-2007 (  658)
  mean number of dayscaptured on the initial postoperative CTA or was subse-quently observed clinically. The negative predictive value of
the initial postoperative CTA for the need for a secondary
procedure is therefore 96.4%, which can be improved to
97.6% with DU surveillance to detect sac expansion
(Table IV).
DISCUSSION
Current guidelines recommend the use of serial CTA
after EVAR to monitor aneurysm expansion, endoleak
formation, graft migration, and structural failures. CTA has
been the mainstay in surveillance due to its advantages of
reproducibility, limited influence by body habitus, and
spatial and contrast resolution. Conversely, concerns re-
garding repetitive contrast administration and exposure to
radiation with CTA also remain high.
Epidemiologic studies of survivors of the atomic bomb
in Japan reveal the cancer risks associated with radiation.
These studies suggest that exposure to 50 mSv of radiation,
about the dose of a single CTA scan, significantly increases
the incidence of cancer.10 More recently, White et al11
found that if screening is initiated at the age of 50, surveil-
patients (blue line) and suprarenal patients (black line).
k circles indicate suprarenal patients.
Table IV. Value of the initial postoperative computed
tomography angiography in predicting the need for
secondary procedures
Variable %
Negative predictive value 96.4
Positive predictive value 50.0
Sensitivity 84.5
Specificity 83.5
Accuracy 83.2renallance CTA scans contribute a total effective radiation dose
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to a predicted 1 new cancer per year per 100 patients as a
consequence of serial post-EVAR CTA surveillance.11 Re-
petitive contrast exposure in serial CTA surveillance after
EVAR has also been linked to worsening renal function.4
More recent reports indicate that contrast nephropathy
affects 7% to 12% of patients after CTA.8
In efforts to reduce exposure to radiation and contrast,
DU is currently being investigated as an alternative to CTA
surveillance after EVAR. Several investigative reports iden-
tify similar sensitivities among CTA and DU imaging in
detecting endoleaks and stent graft abnormalities. In a
single-center paired comparison of DU and CTA imaging
in 236 EVAR patients, Schmeider et al6 determined supe-
rior specificity of DU vs CTA in detecting and correctly
identifying endoleak requiring intervention (90% vs 58%,
P  .05), with similar specificity, negative predictive value,
and positive predictive value among these modalities. Re-
searchers at the UPMC reported the development and
establishment of a DU surveillance program based on evi-
dence of a stable or shrinking aneurysm sac, representing
most of EVAR-treated patients. Not only has this program
been effective, it has resulted in significant cost savings.7
Beeman et al7 reported their single-center experience with
parallel DU and CTA imaging among EVAR patients,
finding similar specificity and sensitivity for detecting en-
doleak (DU: 0.710, 0.990; CTA: 0.731, 0.991). These
authors further estimate that a yearly cost savings of $1595
per patient per year can be realized with the implementa-
tion of a DU post-EVAR surveillance regimen.6-8,12
Although DU seems promising, its major limitations
are interoperator technician variability, large body habitus,
and fasting status. In addition, DU remains to be validated
as a sole modality for post-EVAR surveillance in multi-
center experience and is currently only recommended dur-
ing midterm follow-up as an adjunctive method.2 Hesita-
tion to adopt DU surveillance stems from the recognized
limitations as well as conflicting reports citing low sensitiv-
ity for endoleak detection, which may be attributable to
assessor skill.12
As the popularity and prevalence of EVAR increases,
the negative implications of CTA surveillance and its re-
source requirements will become more significant. We sub-
mit that current guidelines may be recommending overuse
of CTA in low-risk patients with suitable anatomy for
EVAR. Perhaps revised guidelines establishing an appropri-
ate use of CTA and other imaging modalities is warranted.
We found in this cohort that the initial CTA or clinical
presentation identified an abnormality in most patients
necessitating secondary intervention. This experience is
comparable to earlier studies that report identification of
abnormalities in 10% to 15% of patients on the initial
postoperative CTA.13 In contrast, studies report that in
patients with an initial normal CTA, the 6-month CTA had
little value because it identified abnormalities in only 1.5%
of patients, with no clinical significance.14
As more evidence accumulates, the justification for
aggressive CTA surveillance in low-risk patients becomesmore questionable and highlights the necessity to accu-
rately stratify risk. Such an alternative surveillance protocol
is supported by a recent multi-institutional report led by
researchers at Oschner Clinic, who determined from data
from another U.S. Food and Drug Administration pivotal
trial that the absence of early endoleak predicts substantially
reduced risk for subsequent aneurysm-related mortality
(ARM). Specifically, patients without endoleak at 12
months and with significant aneurysm shrinkage have a
subsequent 5-year ARM risk of 5.3%, whereas patients with
endoleak at 30 days have a 5-year ARM risk of 44.1%.14
The European Collaborators on Stent-Graft Tech-
niques for Aortic Aneurysm Repair (EUROSTAR) registry
data show the peak incidence of rupture after EVAR is 18
months, with an annual cumulative risk of rupture of 1%.15
Follow-up studies reveal that in 69% of patients, rupture
was associated with type I or III endoleak, which were easily
identified. Although more challenging to diagnose using
CTA, it is generally accepted that type II leaks should be
treated conservatively unless there is sac expansion.16 As
demonstrated by Wolf et al,17 sac expansion and initial sac
measurement can be determined using DU imaging with a
sensitivity equal to CTA. They report initial sac diameter to
be within 5 mm on the initial study and with nearly equal
measurements evaluating sac expansion on subsequent
studies.17 In contrast, other reports have published identi-
fication of early type II endoleaks to be about 20% on initial
CTA and associate persistent type II endoleaks with an
increased incidence of adverse outcomes.18 We found type
II leaks were the most common of endoleaks and were the
cause of secondary procedures in approximately half of
patients undergoing a secondary procedure.
Our findings, along with published data, demonstrate
the value of the initial CTA to determine stratification of
patients requiring intensive CTA surveillance vs DU sur-
veillance. Our results demonstrate that a negative initial CT
and the absence of clinical findings of limb ischemia are
highly predictive of long-term freedom from secondary
intervention. In addition, the negative predictive value of
the initial CTA, coupled with DU surveillance to identify
sac expansion, may further improve predictability. The
implementation of DU within qualified vascular centers
may be favorable in appropriate patients. To this point,
some studies have found DU imaging to be more sensitive
than CTAwithin centers experienced with bothmethods in
identifying type II endoleak and low-flow leak.19 There-
fore, a proposed strategy of initial post-EVARCT, followed
by subsequent DU imaging, may be justified if the initial
CT shows no abnormalities.
CONCLUSIONS
In low-risk patients with suitable anatomy for EVAR,
most problems that result in subsequent secondary proce-
dures are detected on the initial postoperative CTA or
present with clinical symptoms. A negative result on the
initial post-EVAR CTA is highly predictive of long-term
freedom from secondary intervention. Surveillance CTA
may be overused in this setting. A strategy of initial post-
JOURNAL OF VASCULAR SURGERY
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justified if the initial CTA shows no abnormalities.
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